PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2024
PetVivo Holdings (OTCQB: PETV), a biomedical device company focused on commercializing innovative medical therapeutics for animals, has scheduled its Q3 FY2024 earnings release for Friday, February 14, 2025, after market close. The company will host a conference call and webcast to discuss the results at 2:00 p.m. CT (3:00 p.m. ET) on the same day.
Investors can access the live webcast through PetVivo's Investor Relations website, and a replay will be available following the conference call. The company has also provided dial-in details for those who prefer to join via phone.
PetVivo Holdings (OTCQB: PETV), un'azienda di dispositivi biomedici focalizzata sulla commercializzazione di terapie mediche innovative per animali, ha programmato il rilascio dei risultati del Q3 FY2024 per venerdì 14 febbraio 2025, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica e un webcast per discutere i risultati alle 14:00 CT (15:00 ET) lo stesso giorno.
Gli investitori possono accedere al webcast in diretta tramite il sito web delle Relazioni con gli Investitori di PetVivo, e una registrazione sarà disponibile dopo la conferenza telefonica. L'azienda ha anche fornito informazioni per il collegamento telefonico per coloro che preferiscono partecipare tramite telefono.
PetVivo Holdings (OTCQB: PETV), una empresa de dispositivos biomédicos centrada en la comercialización de terapias médicas innovadoras para animales, ha programado la publicación de resultados del Q3 FY2024 para el viernes 14 de febrero de 2025, después del cierre del mercado. La empresa llevará a cabo una llamada y un webcast para discutir los resultados a las 2:00 p.m. CT (3:00 p.m. ET) ese mismo día.
Los inversores podrán acceder al webcast en vivo a través del sitio web de Relaciones con Inversionistas de PetVivo, y una repetición estará disponible después de la llamada. La empresa también ha proporcionado los detalles de conexión para quienes prefieren unirse por teléfono.
PetVivo Holdings (OTCQB: PETV)는 동물에 대한 혁신적인 의료 치료법을 상용화하는 데 주력하는 생물 의학 장비 회사로서, 2024 회계연도 3분기 실적 발표를 2025년 2월 14일 금요일 시장 종료 후로 예정했습니다. 회사는 같은 날 오후 2시 CT(오후 3시 ET)에 결과를 논의하는 컨퍼런스 콜과 웹캐스트를 개최할 것입니다.
투자자는 PetVivo의 투자자 관계 웹사이트를 통해 생방송 웹캐스트에 접속할 수 있으며, 회의 후 재생도 가능합니다. 또한 전화로 참여하고자 하는 분들을 위해 전화 접속 정보도 제공하였습니다.
PetVivo Holdings (OTCQB: PETV), une société de dispositifs biomédicaux axée sur la commercialisation de thérapies médicales innovantes pour les animaux, a prévu la publication de ses résultats du T3 FY2024 pour le vendredi 14 février 2025, après la clôture du marché. La société organisera une conférence téléphonique et un webinaire pour discuter des résultats à 14h00 CT (15h00 ET) le même jour.
Les investisseurs peuvent accéder au webinaire en direct via le site web des relations avec les investisseurs de PetVivo, et une rediffusion sera disponible après la conférence téléphonique. L'entreprise a également fourni des détails d'appel pour ceux qui préfèrent rejoindre par téléphone.
PetVivo Holdings (OTCQB: PETV), ein biomedizinisches Unternehmen, das sich auf die Vermarktung innovativer medizinischer Therapien für Tiere konzentriert, hat die Ergebnismitteilung für Q3 FY2024 für Freitag, den 14. Februar 2025, nach Marktschluss, geplant. Das Unternehmen wird am selben Tag um 14:00 Uhr CT (15:00 Uhr ET) eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen.
Investoren können den Live-Webcast über die Investor-Relations-Website von PetVivo abrufen, und eine Wiederholung wird nach der Telefonkonferenz verfügbar sein. Das Unternehmen hat auch Anmeldeinformationen für diejenigen bereitgestellt, die lieber telefonisch teilnehmen möchten.
- None.
- None.
MINNEAPOLIS, MN, US, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV and OTCPINK: PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Friday, February 14, 2025 after market close. The company will host a conference call to discuss these results at 2:00 p.m. CT (3:00 p.m. ET) on the same day.
Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo’s Investor Relations website at:
https://audience.mysequire.com/webinar-view?webinar_id=b5c71aaf-5545-4297-93c3-e23bfb001608.
A replay of the webcast will be available through the same link following the conference call. Participants can also access the call using the dial-in details below.
Date: Friday, February 14, 2025
Time: 2:00 p.m CT (3:00 pm ET)
Dial-in: +1 253 215 8782
Meeting ID: 84361016783
Passcode: 632113
About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.
PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company’s commercially launched flagship product, Spryng® with OsteoCushion® Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses.
For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email info1@petvivo.com or visit petvivo.com or sprynghealth.com.
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts.
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
FAQ
When will PetVivo Holdings (PETV) release its Q3 2024 earnings?
What time is PetVivo's (PETV) Q3 2024 earnings conference call?
How can investors access PetVivo's (PETV) Q3 2024 earnings call?
Will there be a replay available for PetVivo's (PETV) Q3 2024 earnings call?
